First Time Loading...

Nexus AG
XETRA:NXU

Watchlist Manager
Nexus AG Logo
Nexus AG
XETRA:NXU
Watchlist
Price: 53.3 EUR 2.7% Market Closed
Updated: May 8, 2024
Section:
 

Relative Value

The Relative Value of one NXU stock under the Base Case scenario is 69.29 EUR. Compared to the current market price of 53.3 EUR, Nexus AG is Undervalued by 23%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NXU Relative Value
Base Case
69.29 EUR
Undervaluation 23%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.8
P/S
P/S
Price to Sales
3.8
vs History
73
vs Industry
33
Median 3Y
4.4
Median 5Y
4.2
Industry
2.4
Forward
3.3
More Details
38.3
P/E
P/E
Price to Earnings
38.3
vs History
92
vs Industry
14
Median 3Y
46.2
Median 5Y
48
Industry
23.4
Forward
29.2
More Details
30.3
P/OCF
P/OCF
Price to OCF
30.3
vs History
31
vs Industry
13
Median 3Y
29.7
Median 5Y
27.5
Industry
15.5
More Details
91.1
P/FCFE
P/FCFE
Price to FCFE
91.1
vs History
11
vs Industry
6
Median 3Y
55.5
Median 5Y
46.3
Industry
23.2
More Details
3.6
P/B
P/B
Price to Book Value
3.6
vs History
92
vs Industry
25
Median 3Y
4.1
Median 5Y
4.8
Industry
2.3
More Details
3.5
EV/S
EV/S
Enterprise Value to Sales
3.5
vs History
80
vs Industry
34
Median 3Y
4
Median 5Y
3.9
Industry
2.5
Forward
3
More Details
4.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.1
vs History
74
vs Industry
51
Median 3Y
4.7
Median 5Y
4.5
Industry
5.3
More Details
16.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
16.2
vs History
76
vs Industry
22
Median 3Y
18.6
Median 5Y
17.9
Industry
12.6
Forward
14
More Details
25.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
25.4
vs History
88
vs Industry
19
Median 3Y
29.6
Median 5Y
29.9
Industry
17.2
Forward
20
More Details
27.4
EV/OCF
EV/OCF
Enterprise Value to OCF
27.4
vs History
42
vs Industry
16
Median 3Y
27.9
Median 5Y
26.2
Industry
15.3
More Details
39.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
39.8
vs History
23
vs Industry
14
Median 3Y
36.8
Median 5Y
32.1
Industry
19.8
More Details
2.8
EV/IC
EV/IC
Enterprise Value to IC
2.8
vs History
87
vs Industry
30
Median 3Y
3.6
Median 5Y
3.6
Industry
2
More Details

Multiples Across Competitors

NXU Competitors Multiples
Nexus AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
Nexus AG
XETRA:NXU
920.2m EUR 3.8 38.3 16.2 25.4
US
Veeva Systems Inc
NYSE:VEEV
32.9B USD 14 63 62.5 67.2
US
Cerner Corp
NASDAQ:CERN
27.9B USD 4.8 47.3 19.6 38.6
US
Change Healthcare Inc
NASDAQ:CHNG
9B USD 2.6 -116.8 16.5 111.6
AU
Pro Medicus Ltd
ASX:PME
11.8B AUD 80.8 169.5 116.5 116.5
JP
M3 Inc
TSE:2413
1.2T JPY 4.9 24.9 13 14.6
US
Inspire Medical Systems Inc
NYSE:INSP
7.4B USD 11.6 -343.3 -185.9 -172.8
US
Doximity Inc
NYSE:DOCS
4.5B USD 9.7 33 22.1 23.5
SE
Sectra AB
STO:SECT B
43B SEK 26.3 101.3 -66.7 -66.7
US
Evolent Health Inc
NYSE:EVH
3.1B USD 1.6 -22.1 25.7 274
US
Goodrx Holdings Inc
NASDAQ:GDRX
3B USD 4 -334.6 36.2 -118.4
P/E Multiple
Earnings Growth
DE
Nexus AG
XETRA:NXU
Average P/E: 68.2
38.3
82%
US
Veeva Systems Inc
NYSE:VEEV
63
139%
US
Cerner Corp
NASDAQ:CERN
47.3
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
Negative Multiple: -116.8 N/A
AU
Pro Medicus Ltd
ASX:PME
169.5
119%
JP
M3 Inc
TSE:2413
24.9
26%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -343.3 N/A
US
Doximity Inc
NYSE:DOCS
33
79%
SE
Sectra AB
STO:SECT B
101.3
56%
US
Evolent Health Inc
NYSE:EVH
Negative Multiple: -22.1 N/A
US
Goodrx Holdings Inc
NASDAQ:GDRX
Negative Multiple: -334.6 N/A
EV/EBITDA Multiple
EBITDA Growth
DE
Nexus AG
XETRA:NXU
Average EV/EBITDA: 36.5
16.2
48%
US
Veeva Systems Inc
NYSE:VEEV
62.5
211%
US
Cerner Corp
NASDAQ:CERN
19.6
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
16.5
N/A
AU
Pro Medicus Ltd
ASX:PME
116.5
124%
JP
M3 Inc
TSE:2413
13
24%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -185.9 N/A
US
Doximity Inc
NYSE:DOCS
22.1
103%
SE
Sectra AB
STO:SECT B
Negative Multiple: -66.7 N/A
US
Evolent Health Inc
NYSE:EVH
25.7
194%
US
Goodrx Holdings Inc
NASDAQ:GDRX
36.2
305%
EV/EBIT Multiple
EBIT Growth
DE
Nexus AG
XETRA:NXU
Average EV/EBIT: 83.9
25.4
70%
US
Veeva Systems Inc
NYSE:VEEV
67.2
238%
US
Cerner Corp
NASDAQ:CERN
38.6
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
111.6
N/A
AU
Pro Medicus Ltd
ASX:PME
116.5
110%
JP
M3 Inc
TSE:2413
14.6
N/A
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -172.8 N/A
US
Doximity Inc
NYSE:DOCS
23.5
116%
SE
Sectra AB
STO:SECT B
Negative Multiple: -66.7 N/A
US
Evolent Health Inc
NYSE:EVH
274
2 086%
US
Goodrx Holdings Inc
NASDAQ:GDRX
Negative Multiple: -118.4 N/A

See Also

Summary
NXU intrinsic value, competitors valuation, and company profile.
DCF Valuation
NXU stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NXU stock valuation using valuation multiples.
Wall Street Estimates
NXU price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NXU stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 135,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.